Keymed Biosciences (HKSE:02162) Total Stockholders Equity : HK$3,266.4 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Total Stockholders Equity?

Keymed Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,266.4 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Keymed Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 was HK$11.81. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Keymed Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.14.

Keymed Biosciences Total Stockholders Equity Historical Data

The historical data trend for Keymed Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Total Stockholders Equity Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-307.07

-1,297.50

4,470.49

3,730.15

3,266.36

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial				4,470.49	4,267.99	3,730.15	3,690.62	3,266.36

Keymed Biosciences (HKSE:02162) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Keymed Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3266.364	-	0)	/	276.604
	=	11.81

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Keymed Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(71.371	+	386.604)	/	3266.364
	=	0.14

Keymed Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines